Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia
Top Cited Papers
- 10 December 2009
- journal article
- clinical trial
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 24 (2), 345-354
- https://doi.org/10.1038/leu.2009.251
Abstract
To access publisher full text version of this article. Please click on the hyperlink in Additional Links fieldAnalysis of 2668 children with acute lymphoblastic leukemia (ALL) treated in two successive Nordic clinical trials (Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL-92 and ALL-2000) showed that 75% of all patients are cured by first-line therapy, and 83% are long-term survivors. Improvements in systemic and intrathecal chemotherapy have reduced the use of central nervous system (CNS) irradiation to <10% of the patients and provided a 5-year risk of isolated CNS relapse of 2.6%. Improved risk stratification and chemotherapy have eliminated the previous independent prognostic significance of gender, CNS leukemia and translocation t(1;19)(q23;p13), whereas the post-induction level of minimal residual disease (MRD) has emerged as a new risk grouping feature. Infant leukemia, high leukocyte count, T-lineage immunophenotype, translocation t(4;11)(q21;q23) and hypodiploidy persist to be associated with lower cure rates. To reduce the overall toxicity of the treatment, including the risk of therapy-related second malignant neoplasms, the current NOPHO ALL-2008 protocol does not include CNS irradiation in first remission, the dose of 6-mercaptopurine is reduced for patients with low thiopurine methyltransferase activity, and the protocol restricts the use of hematopoietic stem cell transplantation in first remission to patients without morphological remission after induction therapy or with high levels of MRD after 3 months of therapyKeywords
This publication has 41 references indexed in Scilit:
- Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 studyBlood, 2009
- Oral Methotrexate/6-mercaptopurine may be Superior to a Multidrug LSA2L2 Maintenance Therapy for Higher Risk Childhood Acute Lymphoblastic LeukemiaJournal of Pediatric Hematology/Oncology, 2009
- Minimal Residual Disease in Acute Lymphoblastic LeukemiaSeminars in Hematology, 2009
- Outcome of treatment in children with hypodiploid acute lymphoblastic leukemiaBlood, 2007
- Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemiaNature, 2007
- Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)Blood, 2006
- Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in SwedenCancer, 2006
- Translocation t(1;19) is related to low cellular drug resistance in childhood acute lymphoblastic leukaemiaLeukemia, 2004
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958